DPP-4 inhibitors × glycemic control

TrialJournal of diabetes and its complications

Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.

Stefano Del Prato et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 2,258 people

Randomised comparison

Lowered glycemic control

−1.10mmol/l−1.70 to −0.50

As reported

difference −1.10 mmol/l, 95% CI −1.70 to −0.50

One number in the abstract

the abstract, start to end

vs. 0.4 mmol/l); treatment difference, 1.1 mmol/l (95% CI, -1.7 to -0.5).

← favours treatmentfavours comparator →
could be chance
Glycemic control
−1.10−1.70 to −0.50
DPP-4 inhibitorsGlycemic control

DPP-4 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.820.82 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

9 papers cite it

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
pooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 23403068